If you haven’t been bombarded with CBD marketing or raves about it from friends, get ready. This extract—which comes from either marijuana or its industrial cousin, hemp—is popping up everywhere. There are CBD capsules, tinctures, and liquids for vaping plus CBD-infused lotions, beauty products, snacks, coffee, and even vaginal suppositories. Already some 1,000 brands of CBD products are available in stores—and online in states that don’t have lenient cannabis laws. This is a tiny fraction of what’s to come: The CBD market is poised to exceed $1 billion by 2020, per the Chicago-based research firm Brightfield Group.
Specifically, I’m talking about hemp as a natural health care product. Most people are aware that hemp fiber has been used for centuries. Betsy Ross is famously believed to have sewn the first U.S. flag using hemp. Thomas Jefferson penned the Declaration of Independence on hemp paper. And Henry Ford’s first Model T was not only designed to run on hemp fuel, but was in fact largely constructed using hemp. (Henry Ford said that the Model T was “grown from the soil.” It had hemp plastic panels that were reputed to be 10 times stronger than steel.) Today, hemp is being used to develop high tech construction materials and super-powered car batteries.
Many mainstream psychiatrists are dissatisfied with the new culture-bound diagnoses, although for partly different reasons. Robert Spitzer, a lead architect of the DSM-III, has argued that adding cultural formulations was an attempt to appease cultural critics, and has stated that they lack any scientific rationale or support. Spitzer also posits that the new culture-bound diagnoses are rarely used, maintaining that the standard diagnoses apply regardless of the culture involved. In general, mainstream psychiatric opinion remains that if a diagnostic category is valid, cross-cultural factors are either irrelevant or are significant only to specific symptom presentations.
^ Harrison, G.; Hopper, K; Craig, T; Laska, E; Siegel, C; Wanderling, J; Dube, KC; Ganev, K; Giel, R; An Der Heiden, W; Holmberg, SK; Janca, A; Lee, PW; León, CA; Malhotra, S; Marsella, AJ; Nakane, Y; Sartorius, N; Shen, Y; Skoda, C; Thara, R; Tsirkin, SJ; Varma, VK; Walsh, D; Wiersma, D (2001). "Recovery from psychotic illness: A 15- and 25-year international follow-up study". The British Journal of Psychiatry. 178 (6): 506–17. doi:10.1192/bjp.178.6.506. PMID 11388966.
^ Demyttenaere, K; Bruffaerts, R; Posada-Villa, J; Gasquet, I; Kovess, V; Lepine, JP; Angermeyer, MC; Bernert, S; et al. (2 June 2004). "WHO World Mental Health Survey Consortium. Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Survey". Journal of the American Medical Association. 291 (21): 2581–2590. doi:10.1001/jama.291.21.2581. PMID 15173149.
exhaustion and pain that kept her on the couch much of the day. The 58-year-old Seattle speech coach didn’t want to take opioid pain-killers, but Tylenol wasn’t helping enough. Roth was intrigued when women in her online chat group enthused about a cannabis-derived oil called cannabidiol (CBD) that they said relieved pain without making them high. So Roth, who hadn’t smoked weed since college but lived in a state where cannabis was legal, walked into a dispensary and bought a CBD tincture. “Within a few hours of placing the drops in my mouth, the malaise and achiness that had plagued me for weeks lifted and became much more manageable,” she says. She took the drops several times a day and in a few weeks was back to her regular life.
We’re proud to announce that our RSHO-Gold™, also known as Pure-Gold™ will be the first CBD listed in the Prescribers’ Digital Reference (PDR)! View our listing here and read the whole story on this history making moment: https://www.benzinga.com/markets/cannabis/19/02/13153490/scoop-one-of-americas-top-pharmaceutical-drug-directories-includes-c Recommended Posts Don’t Miss HempMeds® at This......
^ Sellers, R.; Collishaw, S.; Rice, F.; Thapar, A.K.; Potter, R.; Mars, B.; Harold, G.T.; Smith, D.J.; Owen, M.J.; Craddock, N.; Thapar, A. (2012). "Risk of psychopathology in adolescent offspring of mothers with psychopathology and recurrent depression". The British Journal of Psychiatry. 202 (2): 108–14. doi:10.1192/bjp.bp.111.104984. PMID 23060622.
Hash oils seized in the 1970s had a THC contents ranging from 10 to 30%. The oil available on the U.S. West Coast in 1974 averaged about 15% THC. Samples seized across the United States by the Drug Enforcement Administration over an 18-year period (1980–1997) showed that THC content in hashish and hashish oil averaging 12.9% and 17.4%, respectively, did not show an increase over time. The highest THC concentrations measured were 52.9% in hashish and 47.0% in hash oil. Hash oils in use in the 2010s had THC concentrations as high as 90% and other products achieving higher concentrations 
Thank you for your response. It is still not clear to me. Tricky is an understatement. It appears that it was the DEA that put it on schedule 1 in Dec. 2016, and per legal precedent from the DEA's previous loss at the same effort, in the "Hemp Industries Association v. DEA" legal case 14 years ago, it is being challenged again? The FDA also just closed a consumer comment request on 9/13/17 in collaboration with the UN/WHO review on CBD and the FDA acknowledged it is on Schedule 1, they stated it was the only "beneficial" substance on the list under review.
In 2019, the European Food Safety Authority (EFSA) announced that CBD and other cannabinoids would be classified as "novel foods", meaning that CBD products would require authorization under the EU Novel Food Regulation stating: because "this product was not used as a food or food ingredient before 15 May 1997, before it may be placed on the market in the EU as a food or food ingredient, a safety assessment under the Novel Food Regulation is required." The recommendation – applying to CBD extracts, synthesized CBD, and all CBD products, including CBD oil – was scheduled for a final ruling by the European Commission in March 2019. If approved, manufacturers of CBD products would be required to conduct safety tests and prove safe consumption, indicating that CBD products would not be eligible for legal commerce until at least 2021.
DSM-IV precedes the definition with caveats, stating that, as in the case with many medical terms, mental disorder "lacks a consistent operational definition that covers all situations", noting that different levels of abstraction can be used for medical definitions, including pathology, symptomology, deviance from a normal range, or etiology, and that the same is true for mental disorders, so that sometimes one type of definition is appropriate, and sometimes another, depending on the situation.
Thanks to the passing of the 2018 Farm Bill, zero THC CBD is not illegal in any state in the USA. That’s right; according to federal law, it is legal in all 50 states. That said, since the change in law is relatively new, some states might not fully embrace CBD.This should change with the new bill, however, it may take time. Below we outline four different jurisdictional categories based on pre-2018 Farm Bill practices.
High-profile cases have led to fears that serious crimes, such as homicide, have increased due to deinstitutionalization, but the evidence does not support this conclusion. Violence that does occur in relation to mental disorder (against the mentally ill or by the mentally ill) typically occurs in the context of complex social interactions, often in a family setting rather than between strangers. It is also an issue in health care settings and the wider community.
In the past several years however, public interest in CBD has skyrocketed based on claims — largely unsubstantiated through good clinical research thus far — that it may be a kind of cure-all miracle drug, with therapeutic effects ranging from pain relief to eradicating cancer. In fact, while CBD research has been limited due to federal restrictions, preliminary evidence does suggest that it might help with psychiatric conditions like anxiety disorders (note that while many people claim that CBD is not “psychoactive,” it’s potential as an anxiolytic medication suggests otherwise) and recent randomized, controlled clinical trials suggest a possible role in the treatment of psychotic disorders.2,3 In 2018, the Food and Drug Administration (FDA) approved Epidiolex, a form of CBD manufactured by GW Pharmaceuticals, for the treatment of rare forms of pediatric epilepsy (see my blogpost "Cannabis for Kids: Can Marijuana Treat Childhood Seizures?").
Both of these list categories of disorder and provide standardized criteria for diagnosis. They have deliberately converged their codes in recent revisions so that the manuals are often broadly comparable, although significant differences remain. Other classification schemes may be used in non-western cultures, for example the Chinese Classification of Mental Disorders, and other manuals may be used by those of alternative theoretical persuasions, for example the Psychodynamic Diagnostic Manual. In general, mental disorders are classified separately from neurological disorders, learning disabilities or intellectual disability.
Lobotomy was used in the 20th century as a common practice of alternative treatment for mental illnesses such as schizophrenia and depression. The first ever modern leucotomy meant for the purpose of treating a mental illness occurred in 1935 by a Portuguese neurologist, Antonio Egas Moniz. He received the Nobel Prize in medicine in 1949. . This belief that mental health illnesses could be treated by surgery came from Swiss neurologist, Gottlieb Burckhardt. After conducting experiments on six patients with schizophrenia, he claimed that half of his patients recovered or calmed down. Psychiatrist Walter Freeman believed that "an overload of emotions led to mental illness and “that cutting certain nerves in the brain could eliminate excess emotion and stabilize a personality", according to a National Public Radio article.
As the industry continues to grow, Jones explained that more platforms and websites are popping up, like CBD Oil Review and even Consumer Reports, to help consumers vet these new products. “Even if someone has beautiful packaging and branding, you still have to make sure you are aligning with a partner that can substantiate the claims they are making in the space,” she said. “Someone might have a really big name or be a burgeoning brand but still might not be the right fit, and you don’t want to burn your existing customers.”
A non-intoxicating cannabinoid found in cannabis. After tetrahydrocannabinol (THC), cannabidiol (CBD) is the second-most abundant cannabinoid in the plant, and has many potential therapeutic benefits, including anti-inflammatory, analgesic, anti-anxiety and seizure-suppressant properties. Cannabidiol can be sourced from both marijuana plants and hemp plants, which are legal in most countries as they contain minor amounts of THC.
CBD has proven neuroprotective effects and its anti-cancer properties are being investigated at several academic research centers in the United States and elsewhere. A 2010 brain cancer study by California scientists found that CBD “enhances the inhibitory effects of THC on human glioblastoma cell proliferation and survival.” This means that CBD makes THC even more potent as an anticancer substance. Also in 2010, German researchers reported that CBD stimulates neurogenesis, the growth of new brain cells, in adult mammals.
According to the case report, it was charted by the girl’s oncologist that the patient “suffers from terminal malignant disease. She has been treated to the limits of available therapy … no further active intervention will be undertaken.” She was then placed in a palliative home care and told to prepare for her disease to overwhelm her body. She was expected to suffer a stroke within the next two months.